AR122411A1 - Radioinmunoconjugados dirigidos a tem-1 y sus usos - Google Patents

Radioinmunoconjugados dirigidos a tem-1 y sus usos

Info

Publication number
AR122411A1
AR122411A1 ARP210100884A ARP210100884A AR122411A1 AR 122411 A1 AR122411 A1 AR 122411A1 AR P210100884 A ARP210100884 A AR P210100884A AR P210100884 A ARP210100884 A AR P210100884A AR 122411 A1 AR122411 A1 AR 122411A1
Authority
AR
Argentina
Prior art keywords
radioimmunoconjugates
tem
targeted
pharmaceutical compositions
radioimmunoconjugate
Prior art date
Application number
ARP210100884A
Other languages
English (en)
Inventor
John R Forbes
Ryan W Simms
Eric S Burak
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AR122411A1 publication Critical patent/AR122411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Radioinmunoconjugados que incluyen una porción quelante o un complejo de esta, un conector, y una porción dirigida a TEM-1. Composiciones farmacéuticas de dichos radioinmunoconjugados y métodos para tratar condiciones, p. ej., cáncer, mediante el uso de dichas composiciones farmacéuticas. Reivindicación 11: El radioinmunoconjugado de la reivindicación 8 o una sal farmacéuticamente aceptable de este, donde el radioinmunoconjugado comprende la siguiente estructura: de fórmula (1), donde B es una porción de direccionamiento a TEM-1.
ARP210100884A 2020-04-06 2021-04-06 Radioinmunoconjugados dirigidos a tem-1 y sus usos AR122411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063006040P 2020-04-06 2020-04-06

Publications (1)

Publication Number Publication Date
AR122411A1 true AR122411A1 (es) 2022-09-07

Family

ID=78022984

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100884A AR122411A1 (es) 2020-04-06 2021-04-06 Radioinmunoconjugados dirigidos a tem-1 y sus usos

Country Status (3)

Country Link
AR (1) AR122411A1 (es)
TW (1) TW202204336A (es)
WO (1) WO2021207086A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3233733A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
IL313333A (en) * 2021-12-20 2024-08-01 Astrazeneca Uk Ltd EGFR-CMET-Targeted Compounds and Their Uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202788A1 (en) * 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
PE20211961A1 (es) * 2018-12-03 2021-10-04 Fusion Pharmaceuticals Inc Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn

Also Published As

Publication number Publication date
TW202204336A (zh) 2022-02-01
WO2021207086A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
AR122411A1 (es) Radioinmunoconjugados dirigidos a tem-1 y sus usos
UY38880A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
AR035936A1 (es) Inhibidores de metaloproteinasas de matriz piridinica, derivados de piridina, composiciones farmaceuticas y usos de los mismos en la fabricacion de medicamentos
CL2021002377A1 (es) Conjugados de anticuerpo modulador de empalme - fármaco y métodos de uso. (divisional de solicitud 202003117)
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
AR126251A1 (es) Inhibidores de cdk2
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CO2024001367A2 (es) Compuestos antivirales
ZA202210355B (en) Compositions and therapeutic uses of cannabidiol
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2021017202A2 (es) Compuestos tricíclicos
AR121643A1 (es) Radioinmunoconjugados dirigidos a fgfr3 y usos de estos
AR127496A1 (es) Compuestos de cd73
CR9539A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CO2021002980A2 (es) Formulaciones de dendrímeros
AR127556A1 (es) Métodos para tratar el cáncer utilizando un radioinmunoconjugado
AR124059A2 (es) Conjugados de anticuerpo modulador de empalme-fármaco y métodos de uso
AR119967A1 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
AR129423A1 (es) Compuestos útiles en la terapia contra el hiv

Legal Events

Date Code Title Description
FB Suspension of granting procedure